Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock.
Inotrem was founded in 2013 by Jean-Jacques Garaud, Sébastien Gibot and Marc Derive. The company is headquartered in Paris, France.
Inotrem has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of therapeutic indications such as septic shock and myocardial infarction.
Inotrem’s novel therapeutic approach is driven by a sharp entrepreneurial vision and rooted in internationally recognized cutting-edge science.
Inotrem identified the TREM-1 pathway as a key factor causing unbalanced inflammatory responses. The company focuses on the therapeutic tools derived from knowledge of the biology of TREM-1 pathway.
Inotrem is backed by Kreos Capital, Fountain Healthcare Partners, Bpifrance and others. The company closed its Series B round with €44M on Feb 11, 2020. This brings Inotrem's total funding to €58M to date.